130 related articles for article (PubMed ID: 2313104)
1. A monoclonal antibody which blocks the function of factor D of human complement.
Pascual M; Catana E; Spertini F; Macon K; Volanakis JE; Schifferli JA
J Immunol Methods; 1990 Mar; 127(2):263-9. PubMed ID: 2313104
[TBL] [Abstract][Full Text] [Related]
2. Complement activation pathways in murine immune complex-induced arthritis and in C3a and C5a generation in vitro.
Banda NK; Levitt B; Wood AK; Takahashi K; Stahl GL; Holers VM; Arend WP
Clin Exp Immunol; 2010 Jan; 159(1):100-8. PubMed ID: 19843088
[TBL] [Abstract][Full Text] [Related]
3. Detection of native human complement components C3 and C5 and their primary activation peptides C3a and C5a (anaphylatoxic peptides) by ELISAs with monoclonal antibodies.
Klos A; Ihrig V; Messner M; Grabbe J; Bitter-Suermann D
J Immunol Methods; 1988 Jul; 111(2):241-52. PubMed ID: 3260926
[TBL] [Abstract][Full Text] [Related]
4. The use of monoclonal antibodies as probes of the three-dimensional structure of human complement factor D.
Niemann MA; Kearney JF; Volanakis JE
J Immunol; 1984 Feb; 132(2):809-15. PubMed ID: 6558106
[TBL] [Abstract][Full Text] [Related]
5. The anti-factor D antibody, MAb 166-32, inhibits the alternative pathway of the human complement system.
Tanhehco EJ; Kilgore KS; Liff DA; Murphy KL; Fung MS; Sun WN; Sun C; Lucchesi BR
Transplant Proc; 1999 Aug; 31(5):2168-71. PubMed ID: 10456004
[No Abstract] [Full Text] [Related]
6. Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuits.
Fung M; Loubser PG; Undar A; Mueller M; Sun C; Sun WN; Vaughn WK; Fraser CD
J Thorac Cardiovasc Surg; 2001 Jul; 122(1):113-22. PubMed ID: 11436043
[TBL] [Abstract][Full Text] [Related]
7. Secreted pH-regulated antigen 1 of Candida albicans blocks activation and conversion of complement C3.
Luo S; Hartmann A; Dahse HM; Skerka C; Zipfel PF
J Immunol; 2010 Aug; 185(4):2164-73. PubMed ID: 20644161
[TBL] [Abstract][Full Text] [Related]
8. Measurement of complement activation in rabbit plasma or serum using monoclonal antibodies against C5a.
Bergh K; Iversen OJ
Scand J Immunol; 1989 Mar; 29(3):333-41. PubMed ID: 2470136
[TBL] [Abstract][Full Text] [Related]
9. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation.
Harboe M; Ulvund G; Vien L; Fung M; Mollnes TE
Clin Exp Immunol; 2004 Dec; 138(3):439-46. PubMed ID: 15544620
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of action of factor D of the alternative complement pathway.
Lesavre PH; Müller-Eberhard HJ
J Exp Med; 1978 Dec; 148(6):1498-509. PubMed ID: 82604
[TBL] [Abstract][Full Text] [Related]
11. Complement activation by the alternative pathway is modified in renal failure: the role of factor D.
Pascual M; Paccaud JP; Macon K; Volanakis JE; Schifferli JA
Clin Nephrol; 1989 Oct; 32(4):185-93. PubMed ID: 2805459
[TBL] [Abstract][Full Text] [Related]
12. Factor D of the alternative pathway of bovine complement: isolation and characterization.
Menger M; Aston WP
Vet Immunol Immunopathol; 1984 Oct; 7(3-4):325-36. PubMed ID: 6568787
[TBL] [Abstract][Full Text] [Related]
13. Trypanosoma lewisi: restriction of alternative complement pathway C3/C5 convertase activity.
Sturtevant JE; Balber AE
Exp Parasitol; 1987 Jun; 63(3):260-71. PubMed ID: 3556206
[TBL] [Abstract][Full Text] [Related]
14. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation.
Kroshus TJ; Rollins SA; Dalmasso AP; Elliott EA; Matis LA; Squinto SP; Bolman RM
Transplantation; 1995 Dec; 60(11):1194-202. PubMed ID: 8525509
[TBL] [Abstract][Full Text] [Related]
15. Effects of excess factor D on early- and late-phase activation of the complement cascade.
Kobayakawa H; Miyata T; Inagi R; Shinzato T; Maeda K
Nihon Jinzo Gakkai Shi; 1992 Jan; 34(1):103-6. PubMed ID: 1593792
[TBL] [Abstract][Full Text] [Related]
16. Pre-neutralization of C5a-mediated effects by the monoclonal antibody 137-26 reacting with the C5a moiety of native C5 without preventing C5 cleavage.
Fung M; Lu M; Fure H; Sun W; Sun C; Shi NY; Dou Y; Su J; Swanson X; Mollnes TE
Clin Exp Immunol; 2003 Aug; 133(2):160-9. PubMed ID: 12869020
[TBL] [Abstract][Full Text] [Related]
17. Quantitation of components of the alternative pathway of complement (APC) by enzyme-linked immunosorbent assays.
Oppermann M; Baumgarten H; Brandt E; Gottsleben W; Kurts C; Götze O
J Immunol Methods; 1990 Oct; 133(2):181-90. PubMed ID: 2146321
[TBL] [Abstract][Full Text] [Related]
18. The alternative pathway C3/C5 convertase: chemical basis of factor B activation.
Lesavre PH; Hugli TE; Esser AF; Müller-Eberhard HJ
J Immunol; 1979 Aug; 123(2):529-34. PubMed ID: 458145
[TBL] [Abstract][Full Text] [Related]
19. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
Mayes JT; Schreiber RD; Cooper NR
J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of complement alternative pathway in mice with Fab antibody to recombinant adipsin/factor D.
Pascual M; Catana E; White T; Spiegelman BM; Schifferli JA
Eur J Immunol; 1993 Jun; 23(6):1389-92. PubMed ID: 8500532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
